Nuclear factor kappa B expression in non-small cell lung cancer

Biomed Pharmacother. 2023 Nov:167:115459. doi: 10.1016/j.biopha.2023.115459. Epub 2023 Sep 15.

Abstract

In this mini-review, we discuss the role of NF-κB, a proinflammatory transcription factor, in the expression of genes involved in inflammation, proliferation, and apoptosis pathways, and link it with prognosis of various human cancers, particularly non-small cell lung cancer (NSCLC). We and others have shown that NF-κB activity can be impacted by post-translational S-glutathionylation through reversible formation of a mixed disulfide bond between its cysteine residues and glutathione (GSH). Clinical data analysis showed that high expression of NF-κB correlated with shorter overall survival (OS) in NSCLC patients, suggesting a tumor promotion function for NF-κB. Moreover, NF-κB expression was associated with tumor stage, lymph node metastasis, and 5-year OS in these patients. NF-κB was over-expressed in the cytoplasm of tumor tissue compared to adjacent normal tissues. S-glutathionylation of NF-κB caused negative regulation by interfering with DNA binding activities of NF-κB subunits. In response to oxidants, S-glutathionylation of NF-κB also correlated with enhanced lung inflammation. Thus, S-glutathionylation is an important contributor to NF-κB regulation and clinical results highlight the importance of NF-κB in NSCLC, where NF-κB levels are associated with unfavorable prognosis.

Keywords: Glutathionylation; Lung cancer; NFkB; P50; P65; Redox regulation.

Publication types

  • Review

MeSH terms

  • Carcinoma, Non-Small-Cell Lung* / pathology
  • Gene Expression Regulation
  • Humans
  • Lung Neoplasms* / pathology
  • NF-kappa B / metabolism
  • Protein Processing, Post-Translational

Substances

  • NF-kappa B